- Home
- LILAK vs GENB Comparison
LILAK vs GENB Comparison
Compare LILAK & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LILAK | GENB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | LILAK | GENB |
|---|---|---|
| Price | $8.58 | $16.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $8.20 | ★ $23.20 |
| AVG Volume (30 Days) | ★ 1.3M | 906.1K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,442,200,000.00 | N/A |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | N/A | $16.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.75 | $11.00 |
| 52 Week High | $9.13 | $22.67 |
Technical Indicators
Market Signals| Indicator | LILAK | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 56.21 |
| Support Level | $7.38 | $12.05 |
| Resistance Level | $8.88 | $17.46 |
| Average True Range (ATR) | 0.24 | 1.50 |
| MACD | -0.02 | 0.36 |
| Stochastic Oscillator | 81.05 | 35.99 |
Price Performance
Historical ComparisonAbout LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.